Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

ŞAHİN A., DERİN M. E., ALBAYRAK F., KARAKAŞ B., KARAGÖZ Y.

Advances in Rheumatology, cilt.60, sa.1, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1186/s42358-020-0117-1
  • Dergi Adı: Advances in Rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Anakinra, Canakinumab, Familial Mediterranean fever (FMF), Amyloidosis, Colchicine-resistant, ANTI-IL-1 TREATMENT, RECOMMENDATIONS, MANAGEMENT, SECONDARY, THERAPY
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Introduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis.